Adial Pharmaceuticals, Inc. (NASDAQ:ADIL) Given Consensus Rating of “Hold” by Analysts

Shares of Adial Pharmaceuticals, Inc. (NASDAQ:ADIL) have been given an average rating of “Hold” by the five ratings firms that are covering the company, MarketBeat Ratings reports. One investment analyst has rated the stock with a sell recommendation, one has given a hold recommendation and three have given a buy recommendation to the company. The average 1-year target price among analysts that have issued ratings on the stock in the last year is $15.6250.

ADIL has been the topic of several recent analyst reports. Weiss Ratings reissued a “sell (e+)” rating on shares of Adial Pharmaceuticals in a research report on Friday, July 17th. Loop Capital set a $6.00 target price on Adial Pharmaceuticals in a report on Monday, June 15th. Brookline Capital Markets lowered shares of Adial Pharmaceuticals from a “strong-buy” rating to a “hold” rating in a research report on Thursday, June 11th. Needham & Company LLC cut shares of Adial Pharmaceuticals to a “buy” rating in a report on Monday, June 15th. Finally, Wall Street Zen raised shares of Adial Pharmaceuticals to a “sell” rating in a research report on Saturday, August 15th.

Adial Pharmaceuticals Stock Performance

Shares of NASDAQ:ADIL opened at $7.12 on Friday. The firm has a 50 day simple moving average of $4.02 and a 200 day simple moving average of $2.72. Adial Pharmaceuticals has a 52 week low of $1.31 and a 52 week high of $10.75. The company has a market cap of $18.73 million, a PE ratio of -0.48 and a beta of 1.38.

Adial Pharmaceuticals (NASDAQ:ADIL) last announced its earnings results on Friday, August 14th. The company reported ($11.25) earnings per share (EPS) for the quarter, missing the consensus estimate of ($1.03) by ($10.22).

Insider Activity

In related news, major shareholder Coastlands Capital Lp purchased 10,053 shares of the stock in a transaction dated Thursday, July 9th. The shares were acquired at an average cost of $2.79 per share, for a total transaction of $28,047.87. Following the acquisition, the insider directly owned 383,375 shares in the company, valued at approximately $1,069,616.25. The trade was a 2.69% increase in their position. The purchase was disclosed in a document filed with the SEC, which can be accessed through the SEC website. Over the last three months, insiders have acquired 36,753 shares of company stock worth $97,638. Company insiders own 8.00% of the company’s stock.

Institutional Trading of Adial Pharmaceuticals

A number of institutional investors have recently bought and sold shares of ADIL. Jane Street Group LLC grew its stake in Adial Pharmaceuticals by 887.3% in the fourth quarter. Jane Street Group LLC now owns 121,841 shares of the company’s stock valued at $27,000 after purchasing an additional 109,500 shares in the last quarter. Citadel Advisors LLC purchased a new stake in shares of Adial Pharmaceuticals during the 3rd quarter worth about $51,000. Finally, Armistice Capital LLC purchased a new stake in shares of Adial Pharmaceuticals during the 4th quarter worth about $562,000. Institutional investors and hedge funds own 16.41% of the company’s stock.

Adial Pharmaceuticals Company Profile

Adial Pharmaceuticals, Inc, incorporated in Delaware and founded in 2003, is a clinical-stage specialty pharmaceutical company dedicated to the development of treatments for addiction disorders and central nervous system conditions. The company’s mission centers on creating novel modalities designed to enhance patient adherence and clinical outcomes, particularly in areas of high unmet medical need. Adial leverages sustained-release delivery technologies to address the challenges associated with oral medication regimens in addiction therapy.

The company’s lead product candidate, AD04, is a bioerodible subcutaneous implant engineered to deliver naltrexone continuously over a multi-month period for individuals with alcohol dependence.